NCT02434497View on ClinicalTrials.gov

A Study to Evaluate the Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia

PHASE3CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 6, 2015

Primary Completion Date

November 17, 2016

Study Completion Date

November 17, 2016

Conditions
Homozygous Familial Hypercholesterolemia (HoFH)
Interventions
DRUG

Rosuvastatin 20mg

Active drug 1 or 2 tablets will be taken taken orally, QD, either in the morning or in the evening

Trial Locations (6)

1200

Research Site, Brussels (Woluwé-St-Lambert)

11217

Research Site, Taipei

16150

Research Site, Kubang Kerian

31096

Research Site, Halfa

G7H 7K9

Research Site, Chicoutimi

DK-2100

Research Site, Copenhagen

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY